PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Inorg Biochem. Author manuscript; available in PMC 2010 December 1.
Published in final edited form as:
PMCID: PMC2783361
NIHMSID: NIHMS148419

Complexation of bisphosphonates with Ytterbium(III): Application of phosphate and ATP detection assay based on Yb3+-pyrocatechol violet

Abstract

The coordination chemistry of bisphosphonates with Yb3+ was investigated to evaluate the potential of the UV-Vis based detection method using the Yb3+-pyrocatechol complexation reaction as a sensor for bisphosphonates. The complexation chemistry of Yb3+ with phosphate and ATP analogs was previously described (E. Gaidamauskas et al J. Biol. Inorg. Chem. 13 (2008) 1291-1299), and we here study the complexation chemistry of bisphosphonates in this system. The spectrophotometric assay yields direct evidence for formation of a 4:3 metal to ligand complex at neutral pH. Direct evidence for Yb3+ : methylenebis(phosphonate) complexes with 1:1 and 1:2 stoichiometry was also obtained by potentiometry at acidic and basic pH. Direct evidence for complex formation was obtained using 1H NMR spectroscopy although the stoichiometry was not accessed at neutral pH. Our results suggest that the spectroscopic observation of the YbPV complex can be used to conveniently measure concentrations of bisphosphonates down to 2-3 μM .

Keywords: Bisphosphonate coordination, Ytterbium(III), Pyrocatechol violet, Bisphosphonate detection, UV-vis sensor

1. Introduction

Bisphosphonates, a class of compounds used for treatment of osteoporosis and bone cancer and also important in certain industrial processes, form strong coordination complexes with metal ions in solution.[1, 2] The formation of highly stable metal bisphosphonate complexes with a reporter group could give rise to a spectroscopic change observable by UV-vis or fluorescence spectroscopies can be used as an analytical method for bisphosphonate detection. This is particularly important for those bisphosphonates that do not contain inherent chromophores. Examples of anti-resorptive bisphosphonate drugs include risedronate, zoledronate, ibandronate, alendronate, pamidronate, etidronate and clodronate, [3-5] of which the latter five lack a well-absorbing UV chromophore. α-Halogenated bisphosphonates are also of current interest as components of nucleotide analogs used to probe enzyme mechanisms [6-9] and as potential anti-tumor agents.[10] The coordination chemistry of solution bisphosphonate species is often similar to pyrophosphates [11, 12]. Herein we describe the coordination chemistry of bisphosphonates with Yb3+ which, providing the first example of bisphosphonate detection using a ligand displacement reaction.[13]

Coordination chemistry has been previously used as a strategy for development of phosphate [14] and pyrophosphate [15] sensors. A method that has received attention recently is based on the binuclear Zn2+-dipicolylamine based system, which shows exceptionally strong affinity for both organic and inorganic phosphates.[16] Simple mononuclear metal ion complexes have also been reported for phosphate and organic phosphate detection.[13, 14] Mononuclear metal ion systems based on displacement assemblies have the advantage of simplicity, but the affinity for phosphate is lower because only one coordination center is involved. In the case of pyrophosphate, this advantage is smaller, because the formation constants for simple single metal-pyrophosphate complexes [17] are similar to the formation constants for dinuclear metal-pyrophosphate complexes.[18-21] In this work, we describe the coordination chemistry of pyrophosphate and several bisphosphonates with a simple Yb3+-center, and demonstrate its potential as a sensor for these ligands.

Prior investigation of the coordination chemistry of bisphosphonates has been limited to speciation studies with simple metal ions.[22-24] Several species form, as is also the case with pyrophosphate, but the most important complex for development of ligand displacement detection methods is a 1:1 metal to ligand complex. The solid material that was isolated from saturated solutions of ytterbium and pyrophosphate was found to have a stoichiometry of 4 to 3,[25] although no other structural data are available for it. The selection of metal ions suitable for sensing purposes must be based on their formation of strong complexes with the bisphosphonate ligand, and thus, the simple speciation chemistry reported points to metals such as Cu2+, Zn2+, and rare earth M3+ ions. Direct observation of Cu2+ – bisphosphonate complexation in acidic medium has already been exploited for bisphosphonate detection by UV spectrophotometry.[26]

The indirect detection of HPO42- and ATP was previously accomplished using a ytterbium (Yb3+) pyrocatechol (PV) complex.[13, 27-29] The UV-vis YbPV-method is based on formation of a complex which in the presence of the target ligands undergoes ligand exchange.[13, 27-29] The ligand exchange reaction was conveniently monitored at 623 nm by the disappearance of the Yb3+-pyrocatechol complex, with formation of the colorless Yb-Pi (or Yb-ATP) complex. Although there has been a recent study on pyrophosphate sensing,[15] no studies have previously considered the possibility of bisphosphonate detection using ligand displacement sensors.

The chelating properties of bisphosphonates and their several protonation states indicate potential formation of several complexes depending on the pH and the substitution on the bridging methylene between the two phosphorus atoms.[2] As noted above, a 1:1 complex has been structurally characterized for Yb3+ and PPi in the solid state,[30] however, the 4 to 3 solid isolated from aqueous saturated solution [25] has not been structurally characterized. The properties of a range of hydrated rare-earth (including Yb3+) PPi complexes prepared from hydrothermal synthesis was investigated using XRD, IR, and NMR spectroscopies as well as X-ray crystallography.[31] Solution studies with methylenebis(phosphonic acid) and 1-hydroxyethylidene-1,1-bis(phosphonic acid) suggest the existence of both the 1:1 and 1:2 complexes with other lanthanides.[32] The solid 1:2 complexes between 1-hydroxyethylidene-1,1-bis(phosphonic acid) and lanthanides yield different stoichiometries when hydrated in solution.[33] Given the number of possible complexes that can form in an aqueous system, any assay based on complexation chemistry must investigate the nature of the complex that gives rise to the spectroscopic signal.

Herein we report studies using the Yb-PV system to define its complexation chemistry in the presence of several bisphosphonates and to evaluate the potential of the Yb-PV system for measuring low bisphosphonate concentrations at neutral pH.

2. Experimental

Reagent Stock solutions

The 10 mM stock solutions of PV and YbCl3 were prepared by dissolving PV and YbCl3 6H2O (both from Sigma Aldrich) in deionized water. The PV stock solution was standardized at pH 5.3 in 10 mM acetate buffer solution, based on the average molar absorbance value of 14000 M-1cm-1 at 445 nm,[34] and the Yb3+ stock solution was standardized by complexometric titration with Na2H2EDTA at pH 6.0 in acetate buffer using xylenol orange as an indicator.[35] These studies were developed based on standardization curves similar to those reported previously.[34, 35]

Analyte Solutions

The 10 mM analyte stock solutions were prepared by dissolving methylenebis(phosphonic acid), 1-hydroxyethylidenebis(phosphonic acid), anhydrous tetrasodium pyrophosphate (all three from Aldrich), and tetrasodium difluoromethylenediphosphonate [36] in water. The (4-amino-1-hydroxybutylidene)bis(phosphonic acid) monosodium salt trihydrate and [1-hydroxy-2-(3-pyridinyl)ethylidene]bis(phosphonic acid) monosodium salt were donated by Procter & Gamble, and (3-amino-1-hydroxypropylidene)bis(phosphonic acid) was a gift from Novartis. The purity of bisphosphonates was routinely checked by 31P NMR and elemental analysis. The analyte stock solution concentrations were verified by potentiometric titration with ~0.2 M KOH under a CO2-free atmosphere.

General Procedure

The 50 μM YbPV sensor [13] was prepared in situ by adding YbCl3 stock solution first and PV stock solution next to 5.0 mL of 10 mM HEPES buffer at pH 7.0. Aliquots of 10 mM analyte stock solutions were added last with shaking, and after ~1min the UV-vis spectrum was recorded in a quartz cuvette. The UV-Vis spectra were acquired at ambient temperature on a PerkinElmer Lambda 25 spectrophotometer in dual beam mode using 10 mM HEPES buffer as a blank. Water purified by the E-pure system from Barnstead up to 17.8 MΩ·cm was used throughout.

3. Results and Discussion

3.1 Sensing of pyrophosphate and its bisphosphonate analogues by YbPV in 10 mM HEPES buffer at pH 7.0

The complexation of pyrophosphate, and etidronate as a representative bisphosphonate compound, with Yb3+ was investigated using the colorimetric assay described by eq. (1).[13, 27-29] The UV-vis spectra of a mixture of 50 μM Yb3+ and 50 μM PV in 10 mM HEPES pH 7.0 acquired upon successive addition of pyrophosphate and etidronate are shown in Figure 1.

Figure 1Figure 1
Absorbance spectra of 50 μM of Pyrocatechol Violet (PV), 50 μM of Yb3+-PV complex (YbPV), and 50 μM of YbPV upon successive addition of tetrasodium pyrophosphate PPi (a) and etidronate (b) in 10 mM HEPES buffer (pH 7.0)
Yb+PV=YbPV
(1)
4YbPV+3PPi=Yb4(PPi)3+4PV
(2)

Absorbance differences at 443 and 623 nm plotted as a function of analyte concentration are shown in Figures 2a and 2b. The Yb3+ is sequestered from a relatively weak Yb-PV complex to form a more stable Yb3+- pyrophosphate or Yb3+- etidronate complex. However, in contrast to the linear response to phosphate concentration, showing formation of a 1:1 Yb – phosphate complex as reported previously, the absorbance difference versus analyte concentration plot shows two lines with distinctly different slopes (Figure 2): a linear ΔA response to a low analyte concentration, and a zero-slope (no change in ΔA) response at a high analyte concentration. The intersection point of these two lines at the molar metal to ligand ratio of 1.34±0.03 reflects the 4 : 3 complex stoichiometry. These results suggest that this Yb – analyte complex stoichiometry is different from that of Yb – phosphate, the most simple interpretation corresponding to the empirical formula Yb4(P2O7)3, and Yb4(etidronate)3. Identical stoichiometry was observed for methylenebis(phosphonate) and (difluoro)methylenebis(phosphonate) (Figures 2c and 2d), even though the pKa’s corresponding to the first protonation step in the series of analytes PCF2P, PPi, PCH2P, and etidronate extend from 7.8 (PCF2P) to 10.7 (etidronate).

Figure 2Figure 2Figure 2Figure 2
Absorbance differences in 50 μM Yb3+ and 50 μM PV solutions in 10 mM HEPES buffer (pH 7.0) as a function of added pyrophosphate (a), etidronate (b), methylenebis(phosphonate) (c), and (difluoro)methylenebis(phosphonate) (d) concentrations ...

The detection limits2 for pyrophosphate and etidronate are 1.6 μM and 3.0 μM, respectively. The observed concentration ranges for a linear absorbance response to bisphosphonate addition is from 2 μM to 35 μM. The two phosphonate groups in bisphosphonates are known to act as a “bone hook” in binding to hydroxyapatite [37] and the binding affinity is increased by the availability of an α-OH group.[38] We see no evidence for such an increase in affinity, suggesting that the species in solution and the 4:3 solid state complex do not involve significant coordination by the OH group. Solution studies with Ca2+ complexes did not find differences in formation constants based on this OH group either.[39]

3.2 Methylenebisphosphonate interaction with Yb3+ as monitored by potentiometric and 1H NMR titration

Several attempts to probe the Yb3+ - PXPi complex structure at millimolar concentration were made, and the most successful results, unfortunately outside the neutral pH-range, obtained for PCH2P as a ligand, are presented in this section. Potentiometric studies of Yb3+ - pyrophosphate and Yb3+- PCH2P were attempted in 0.4 M KCl. Insoluble species formation in the reliable pH range from 2 to 11 precluded the potentiometrical characterization of the ytterbium ion solution with pyrophosphate, and only limited pH ranges (2.5-2.7 and 8.5 to 11.2) were accessible in the case of PCH2P at a metal-to-ligand ratio of 1:4. Only two complex species, Yb(PCH2P)- and Yb(PCH2P)25- were detected by a fitting procedure using PSEQUAD.[40] Attempts to include other species, such as Yb4(PCH2P)3, were rejected. The soluble species forming in solution detected by potentiometric titration are summarized in Table 1. The formation constants of two complexes [Yb(PCH2P)]- and [Yb(PCH2P)2]5- should be viewed with caution due to the very limited pH range available for titration. The titration data analysis shows that for example in 0.5 mM Yb3+ and 2 mM PCH2P4- (0.4 M KCl) solution, only the 1:1 complex [Yb(PCH2P)]- forms at acidic pH (2.5-2.7). After reaching pH~3, precipitation begins, and the amount of precipitate increases upon further addition of a base until neutral pH is attained. The precipitate re-dissolves completely at pH ~8.5. Over the pH range 8.5 to 11.2, both the 1:1 and 1:2 ([Yb(PCH2P)2]5-) complexes form in solution.

Table 1
Species formation constants (as logarithms of total formation constants) in the ternary system H+ - PXP4- - Yb3+ in 0.4 M KCl at 25°C.

A previous study of the Yb - pyrophosphate speciation [25] showed the presence of two soluble species [Yb(P2O7)]-, and [Yb(P2O7)2]5-, and one insoluble Yb4(P2O7)3 species. Using these formation constants a speciation simulation under our assay conditions (50 μM of Yb3+ at pH 7.0) predicts that Yb4(P2O7)3 predominates in the high Yb:PPi ratio region, whereas after reaching equivalent ratio of Yb:PPi in the range of 1.33 to 1, the abundance of the 1:1 YbPP complex increases rapidly (Figure S1). We attempted to verify this system using potentiometry, but precipitation in this region prevailed as expected based on the concentrations needed to carry out the experiment.

Under our assay conditions (50 μM Yb3+, 50 μM PPi, 10 mM Hepes, pH 7.0) we did not observe any precipitates. We provide two possible explanations. First, precipitates may form in solution, but are too fine to be observed visually. Our studies confirmed that at higher (millimolar) concentrations visible precipitation indeed forms. Alternatively, precipitate formation often requires concentrations above the limit defined by the solubility product, and, as a result, precipitates are first formed at higher concentrations. Both types of explanations have merit. The ability to see very low levels of precipitates is limited; we found that at the 50 μM level of material it was difficult to see the precipitate. Alternative interpretations of the results from the spectrophotometric assay include the possibility that the 4:3 complex is a soluble complex. If one assumes formation of a soluble Yb4(P2O7)3 complex, the spectrophotometric data can be explained by invoking the formation of [Yb4(P2O7)3] with the log β lower limit of 69±1. We do not favor this interpretation because the potentiometric studies did not support formation of the soluble Yb4(P2O7)3 complex.

1H NMR studies were also undertaken to obtain more information on this system. Given the paramagnetic nature of Yb3+, the presence of this ion affects the relaxation times of all solution components and line broadening would be anticipated for both free and coordinated PV. In Figure 3 we show the 1H NMR spectra of solutions of PCH2P with varying amounts of Yb3+. The presence of Yb3+ increases the linewidth as anticipated, but in addition, the chemical shift changes. This is indicative that there is some interaction between the Yb3+ and the PCH2P consistent with complex formation even at very low metal to ligand ratios. As the amount of Yb3+ increases, a broad signal at ~1.5 ppm is observed and the 2 ppm signal decreases. The 1.5 ppm signal is only observed when the ratio of Yb3+ to PCH2P decreases to 1:4. At a ratio of 1:2, the PCH2P signal at 1.5 ppm exceeds that of the complex. At the 1:1 ratio this signal is the major signal and very little if any free PCH2P is detectable. A precipitate was observed at the ratio 1:1 and above (spectra at 2:1 and 4:1 not shown), and we therefore did not attempt to extract stoichiometries for the complex(es).

Figure 3
1H NMR spectra of 2 mM PCH2P solutions with increasing amounts of Yb3+. The Yb3+ to PCH2P ratio is shown next to each spectrum. The solution pH’s are between 7.0 and 7.2. Precipitation was observed in samples of ratios 1:1 and 1:2. An * denotes ...

Two signals are observed in the 1H NMR spectrum in the presence of PCH2P. Since one of these is formed at high ligand to metal ion concentration, this signal is due to free ligand or some complex or the equilibrium between the two. Given the high ligand ratio it is likely that some free ligand will exist in solution. Speciation would support the possibility that a complex is formed and if only one complex is formed, that the observed signal is the average of a complexed and free ligand or only the ligand. We favor the possibility that the 2 ppm signal is due to free ligand and not a soluble Yb4(PCH2P)3 complex. The second broad signal at 1.5 ppm is shifted upfield from the ligand, and only forms at higher metal ion to ligand ratios. This is likely a complex with a stochiometry near 1:1, which predominates at low concentrations near 1:1.5 metal ion and ligand (and below ratios of 1:1.5).

3.3 YbPV assay response towards the bisphosphonate drugs pamidronate, alendronate and residronate in HEPES buffer at pH 7.0

The possibility that bisphosphonate drugs can be determined from the complex Yb3+ forms with PV at pH 7.0 in aqueous solution, was confirmed by the studies described above with etidronate in which the bridge carbon bears a methyl and a hydroxy substituent. The assay was further used with bisphosphonate drugs in which the methyl group is replaced by a primary aminoethyl, aminopropyl, or 3-pyridylmethyl substituent. The spectra of 50 μM YbPV upon addition of pamidronate, alendronate, and residronate were very similar to those obtained for etidronate. Similar spectroscopic signatures suggest that all these systems form the same types of complexes regardless of the functional groups in the bisphosphonate moiety. In Figure 4 we show the absorbance spectral difference at 443 and 623 nm as a function of pamidronate concentration. As in the case of etidronate, the intersection point at 37 μM of analyte suggests the same 4:3 Yb3+ - pamidronate complex stoichiometry. Studies with aledronate and residronate were carried out at neutral pH yielding the same 4:3 stoichiometry for the complexes (data not shown).

Figure 4
Absorbance difference in the 50 μM Yb3+ and 50 μM PV solution in 10 mM HEPES buffer (pH 7.0) as a function of pamidronate concentration.

Previous approaches to detect phosphates, pyrophosphates and nucleotides have been based on electrochemical,[41] conductive,[42] refractive index [43-45] and fluorescence [46, 47] methods and as such are limited by the nature of the analyte or eluent phase. At the price of adding steps to the analytical procedure, chemical derivatization can offer added sensitivity,[47-49] but indirect detection methods also represent a promising strategy for analytical detection of these classes of compounds.[42, 50-53] Existing spectrophotometric methods for specific bisphosphonates that lack an inherent chromophore have been based upon ceric sulfate oxidation [54, 55] (etidronate) or ninhydrin [55] (alendronate) show similar sensitivity, with detection limits from 3 μM to 6 μM. More sensitive spectrophotometric assays for risedronate based on a Cu2+ complex have been reported in the literature [56] with a claimed detection limit of 95 nM. This method exploits the intrinsic high molar absorptivity of the pyridine side chain substituent of the drug. Our new indicator displacement assay using the YbPV complex as a sensor is general and including bisphosphonates lacking any chromophore. This approach has the further advantage of being equivally sensitive for all tested bisphosphonate compounds. It is likely that this sensor can be usefully applied to detecting other bisphosphonates with featureless UV-vis spectra, such as clodronate, ibandronate and others.

In our previous study [13] we showed that YbPV is sensitive to phosphate and ATP, thus one limitation of this new bisphosphonate sensor is that it will not be selective relative to these species, which if present would need to be removed before analysis. Work is in progress to find more selective sensing systems.

4. Conclusion

The coordination complexes that form between Yb3+ and bisphosphonates were investigated at pH 7.0 to explore the feasibility of using this chemistry to measure bisphosphonate concentrations by visible spectroscopic detection of PV displaced by the bisphosphonate from an initial YbPV complex. Previous literature relating to the pyrophosphate ligand suggested that the complex should form either a 1:1, a 1:2 or a 4:3 solid.[25] We found direct evidence by complex formation by potentiometry, UV-vis and 1H NMR spectroscopy. Evidence for both 1:1 and 1:2 complexes Yb-methylenebis(phosphonate) complexes by potentiometry at acidic and basic pH values was obtained, and for a 4:3 complex at neutral pH by a novel spectrophotometric assay we recently described.[13]

Although the Yb3+ complex that forms with pyrophosphate is somewhat stronger than that with the bisphosphonates examined as potential ligands, the bisphosphonate complexes were sufficiently strong to quantitatively displace PV from YbPV. Equivalent results were obtained with bisphosphonate drugs having alkyl, aminoalkyl or heterocyclic side chains (etidronate, pamidronate, alendronate and risedronate). This assay will measure total phosphorus content in samples containing multiple phosphorus compounds because of the high affinity for a range of phosphates. The advantage of this simple, sensitive (low μM detection limit) colorimetric sensor for direct spectrophotmetric detection of bisphosphonates resides in the fact that the displaced indicator spectrum is independent of the analyte and thus should be applicable to many bisphosphonate compounds with diverse bridge carbon substitution.

Supplementary Material

01

Acknowledgement

DCC and CEM thank the National Institutes of Health for funding this work (Grant 1U19CA105010).

Abbreviations

PCF2P
(difluoro)methylenebis(phosphonate)
PCH2P
methylenebis(phosphonate)
PXP
generic formula for a bisphosphonate with a X group between the two phosphate groups
Pi
phosphate
PPi,
pyrophosphate
PV
pyrocatechol violet
NMR
nuclear magnetic resonance
Yb-PV
this means a complex formed between Yb3+ and PV.
Yb3+
ytterbium +3 cation

Footnotes

2The detection limit was evaluated as the ratio 3·s/b (s is the standard error of the regression, and b is the slope of the linear fit)

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

[1] Matczak-Jon E, Videnova-Adrabinska V. Coord. Chem. Rev. 2005;249:2458–2488.
[2] Popov K, Ronkkomaki H, Lajunen LHJ. Pure App. Chem. 2001;73:1641–1677.
[3] Rogers MJ, Watts DJ, Russell RGG. Cancer. 1997;80:1652–1660. [PubMed]
[4] Russell RGG, Rogers MJ. Bone. 1999;25:97–106. [PubMed]
[5] Licata AA. Ann. Pharmacother. 2005;39:668–677. [PubMed]
[6] Sucato CA, Upton TG, Kashemirov BA, Osuna J, Oertell K, Beard WA, Wilson SH, Florian J, Warshel A, McKenna CE, Goodman MF. Biochemistry. 2008;47:870–879. [PubMed]
[7] Sucato CA, Upton TG, Kashemirov BA, Batra VK, Martinek V, Xiang Y, Beard WA, Pedersen LC, Wilson SH, McKenna CE, Florian J, Warshel A, Goodman MF. Biochemistry. 2007;46:461–471. [PubMed]
[8] McKenna CE, Kashemirov BA, Upton TG, Batra VK, Goodman MF, Pedersen LC, Beard WA, Wilson SH. J. Am. Chem. Soc. 2007;129:15412–15413. [PMC free article] [PubMed]
[9] Upton TG, Kashemirov BA, McKenna CE, Goodman MF, Prakash GKS, Kultyshev R, Batra VK, Shock DD, Pedersen LC, Beard WA, Wilson SH. Org. Lett. 2009;11:1883–1886. [PMC free article] [PubMed]
[10] Gulley JD, Dahut WL. Expert Rev. Anticanc. 2005;5:221–230. [PubMed]
[11] Blackburn GM, Eckstein F, Kent DE, Perree TD. Nucleos. Nucleot. Nucleic Acids. 1985;4:165–167.
[12] Ma QF, Babbitt PC, Kenyon GL. J. Am. Chem. Soc. 1988;110:4060–4061.
[13] Gaidamauskas E, Saejueng K, Holder AA, Bharuah S, Kashemirov BA, Crans DC, McKenna CE. J. Biol. Inorg. Chem. 2008;13:1291–1299. [PubMed]
[14] Spangler C, Schaeferling M, Wolfbeis OS. Microchim. Acta. 2008;161:1–39.
[15] Kim SK, Lee DH, Hong JI, Yoon J. Acc. Chem. Res. 2009;42:23–31. [PubMed]
[16] Sakamoto T, Ojida A, Hamachi I. Chem. Commun. 2009:141–152. [PubMed]
[17] Smith RM, Martell AE, Motekaitis RJ. NIST Critically Selected Stability Constants of Metal Complexes Database. Gaithersburg, MD: U.S. Department of Commerce; 2004.
[18] Ojida A, Mito-oka Y, Inoue M, Hamachi I. J. Am. Chem. Soc. 2002;124:6256–6258. [PubMed]
[19] Ojida A, Mito-oka Y, Sada K, Hamachi I. J. Am. Chem. Soc. 2004;126:2454–2463. [PubMed]
[20] Morgan BP, He S, Smith RC. Inorg. Chem. 2007;46:9262–9266. [PubMed]
[21] Khatua S, Choi SH, Lee J, Kim K, Do Y, Churchill DG. Inorg. Chem. 2009;48:2993–2999. [PubMed]
[22] Sanna D, Micera G, Buglyo P, Kiss T. J. Chem. Soc., Dalton Trans. 1996:87–92.
[23] Nash KL, Rao LF, Choppin GR. Inorg. Chem. 1995;34:2753–2758.
[24] Rizkalla EN, Zaki MTM, Ismail MI. Talanta. 1980;27:715–719. [PubMed]
[25] Sheka ZA, Sinyavskaya EI. Russ. J. Inorg. Chem. 1966;11:555–560.
[26] Ejiri N, Onishi M. Detection or determination of bisphosphonates. 2002. JP 2002005839.
[27] Yin CX, Gao F, Huo FJ, Yang P. Chem. Comm. 2004:934–935. [PubMed]
[28] Yin CX, Huo FJ, Yang P. Sens. Actuators, B. 2005;109:291–299.
[29] Yin CX, Huo FJ, Yang P. Anal. Bioanal. Chem. 2006;384:774–779. [PubMed]
[30] Ferid M, Horchani-Naifer K, Trabelsi-Ayedi M. Z. Kristallogr. - New Cryst. Struct. 2004;219:353–354.
[31] Ben Moussa S, Sobrados I, Iglesias JE, Trabelsi-Ayedi M, Sanz J. J. Mater. Chem. 2000;10:1973–1978.
[32] Nash KL, Rao L-F, Choppin GR. Inorg. Chem. 1995;34:2753.
[33] Nash KL, Rogers RD, Ferraro J, Zhang J. Inorg. Chim. Acta. 1998;269:211–223.
[34] Hulanicki A, Glab S, Ackermann G. Pure Appl. Chem. 1983;55:1137–1230.
[35] Lyle SJ, Rahman M. Talanta. 1963;10:1177–1182.
[36] Crans DC, Holder AA, Saha TK, Prakash GKS, Yousufuddin M, Kultyshev R, Ismail R, Goodman MF, Borden J, Florian J. Inorg. Chem. 2007;46:6723–6732. [PubMed]
[37] Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RGG, Ebetino FH. Bone. 2006;38:617–627. [PubMed]
[38] Russell RGG. Bone. 2007;40:S21–S25.
[39] Claessens RAMJ, Vanderlinden JGM. J. Inorg. Biochem. 1984;21:73–82.
[40] Zekany L, Nagypal I, Peintler G. 2008. PSEQUAD v 5.10.
[41] Usui T, Watanabe T, Higuchi S. J. Chromatogr. 1992;584:213–220. [PubMed]
[42] Tsai EW, Ip DP, Brooks MA. J. Chromatogr. 1992;596:217–224. [PubMed]
[43] Quitasol J, Krustins L. J. Chromatogr. A. 1994;671:273–279.
[44] Han MS, Yim DH. Bull. Korean Chem. Soc. 2004;25:1151–1155.
[45] Han MS, Kim DH. Angew. Chem. Int. Ed. 2002;41:3809–3811. [PubMed]
[46] Lovdahl MJ, Pietrzyk DJ. J. Chromatogr. A. 1999;850:143–152. [PubMed]
[47] Peng SX, Dansereau SM. J. Chromatogr. A. 2001;914:105–110. [PubMed]
[48] Daley-Yates PT, Gifford LA, Hoggarth CR. J. Chromatogr. 1989;490:329–338. [PubMed]
[49] Qin X-Z, Tsai EW, Sakuma T, Ip DP. J. Chromatogr. A. 1994;686:205–212.
[50] Tsai EW, Chamberlin SD, Forsyth RJ, Bell C, Ip DP, Brooks MA. J. Pharm. Biomed. Anal. 1994;12:983–991. [PubMed]
[51] Kline WF, Matuszewski BK, Bayne WF. J. Chromatogr. 1990;534:139–149. [PubMed]
[52] Kline WF, Matuszewski BK. J. Chromatogr. B. 1992;583:183–193. [PubMed]
[53] Sparidans RW, den Hartigh J. Pharm. World Sci. 1999;21:1–10. [PubMed]
[54] Kuljanin J, Jankovic I, Nedeljkovic J, Prstojevic D, Marinkovic V. J. Pharm. Biomed. Anal. 2002;28:1215–1220. [PubMed]
[55] Taha EA, Youssef NF. Chem. Pharm. Bull. 2003;51:1444–1447. [PubMed]
[56] Walash MI, Metwally ME-S, Eid M, El-Shaheny RN. Int. J. Biomed. Sci. 2008;4:303–309. [PMC free article] [PubMed]